New drug cocktail aims to wipe out Hard-to-Treat blood cancers
NCT ID NCT04941716
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a combination of two oral drugs, acalabrutinib and venetoclax, in 20 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to treatment. The goal is to see if the combo can reduce cancer cells to undetectable levels in the blood. Participants will take both pills by mouth and undergo regular blood tests, scans, and bone marrow exams to monitor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib and venetoclax
- What this could lead to
- If successful, this combination could offer a more effective, chemotherapy-free option for people with CLL or SLL that has returned or not responded to prior treatment.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 20 participants, so results may not apply to everyone. Side effects from the drug combination are possible, and it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack
- New Two-Step transplant shows promise for blood cancer patients